Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Coherus Oncology (CHRS) over the last 7 years, with Q3 2025 value amounting to $3.7 million.

  • Coherus Oncology's Other Operating Expenses rose 3635.03% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.3 million, marking a year-over-year increase of 26470.09%. This contributed to the annual value of $117.6 million for FY2024, which is 14130.83% up from last year.
  • Latest data reveals that Coherus Oncology reported Other Operating Expenses of $3.7 million as of Q3 2025, which was up 3635.03% from $3.4 million recorded in Q2 2025.
  • Coherus Oncology's 5-year Other Operating Expenses high stood at $111.6 million for Q4 2024, and its period low was -$108.5 million during Q3 2022.
  • In the last 5 years, Coherus Oncology's Other Operating Expenses had a median value of $3.7 million in 2025 and averaged -$3.6 million.
  • In the last 5 years, Coherus Oncology's Other Operating Expenses plummeted by 74524.95% in 2022 and then skyrocketed by 24007.76% in 2024.
  • Coherus Oncology's Other Operating Expenses (Quarter) stood at $12.1 million in 2021, then tumbled by 745.25% to -$78.1 million in 2022, then decreased by 1.99% to -$79.7 million in 2023, then skyrocketed by 240.08% to $111.6 million in 2024, then tumbled by 96.67% to $3.7 million in 2025.
  • Its Other Operating Expenses stands at $3.7 million for Q3 2025, versus $3.4 million for Q2 2025 and $2.7 million for Q1 2025.